Immunotoxins Containing Pseudomonas Exotoxin that Target Ley Damage Human Endothelial Cells in an Antibody-Specific Mode: Relevance to Vascular Leak Syndrome

Clinical Cancer Research

Volumn 1, Issue 12, 1995, Pages 1589-1594

  Kuan, Chien Tsun ^a   Pai, Lee H ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY B3; PSEUDOMONAS EXOTOXIN; RECOMBINANT IMMUNOTOXIN LMB 1; UNCLASSIFIED DRUG;

ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ETIOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VASCULAR LEAK SYNDROME;

ADP RIBOSE TRANSFERASES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BACTERIAL TOXINS; CAPILLARY LEAK SYNDROME; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; EXOTOXINS; HUMANS; IMMUNOTOXINS; LEWIS BLOOD-GROUP SYSTEM; PROTEINS; VIRULENCE FACTORS;

EID: 0029569061     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Grossbard, M. L., and Nadler, L. M. Immunotoxin therapy of malignancy. In: V. T. DeVita, S. Heilman, and S. Rosenberg (eds.), Important Advances in Oncology, pp. 111–135. Philadelphia: J. B. Lippincott, pp. 521–533, 1992.
2. Pai, L. H., and Pastan, I. Monoclonal antibodies in cancer therapy: immunotoxins and recombinant toxins. In: V. T. DeVita, S. Heilman, and S. Rosenberg (eds.), Biologic Therapy of Cancer, Ed. 2, pp. 521–533, Philadelphia: J. B. Lippincott, 1994.
3. Vitetta, E. S., and Thorpe, P. E. Immunotoxins containing ricin or its A chain. Semin. Cell Biol., 2: 47–58, 1991.
4. Pastan, I., and FitzGerald, D. J. Recombinant toxins for cancer treatment. Science (Washington DC), 254: 1173–1177, 1991.
5. Tazzari, P. L., Bolognesi, A., De Totero, D., Falini, B., Lemoli, R. M., Soria, M. R., Pileri, S., Gobbi, M., Stein, H., Flenghi, L., Vartelli, M. F., and Stirpe, F. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin’s disease and CD30+ lymphoma: in vitro evaluation. Br. J. Haematol., 81: 203–211, 1992.
6. Uckun, F. M., Manivvel, C., Arthur, D., Chelstrom, L. M., Finnegan, D., Tuel-Ahlgren, L., Irvin, J. D., Myers, D. E., and Gunther, R. In vivo efficacy of B43 (anti-CD 19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79: 2201–2214, 1992.
7. Vitetta, E. S., Stone, M., Amolt, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W., and Thorpe, P. E. Phase I immunotoxin trial in patients with B cell lymphoma. Cancer Res., 51: 4052–4058, 1991.
8. Grossbard, M. L., Freeman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L., Spector, N., Dear, K., Lambert, J. M., Blattler, W. A., Taylor, J. A., and Nadler, L. M. Serotherapy of B cell neoplasm with anti-B4 blocked ricin: a phase I trial of daily bolus infusion. Blood, 79: 576–585, 1992.
9. Weiner, L. M., O’Dwyer, J., Kitson, J., Comis, R. L., Frankel, A. E., Bauer, R. J., Konrad, M. S., and Growes, E. S. Evaluation of an anti-breast carcinoma monoclonal antibody 260F90 recombinant ricin A chain immunoconjugate. Cancer Res., 49: 4062–4067, 1989.
10. Spitler L., del Rio, M., Khentigan A., Wedel N. I., Brophy N. A., Miller L. L., Harkonen, W. S., Rosendorf, L. L., Lee, H. M., and Mischak, R. P. Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody ricin-A chain immunotoxin. Cancer Res., 47: 1717–1723, 1987.
11. Byers, V. S., Rodvien, R., Grant, K., Durrant, L. G., Hudson, K. H., and Baldwin, R. W. Phase I study of monoclonal antibody-ricin A chain immunotoxin xXomaZyme 791 in patients with metastatic colon cancer. Cancer Res., 49: 6153–6160, 1989.
12. Siegall, C. B., Chaudhary, V. K., FitzGerald, D. J., and Pastan, I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J. Biol. Chem., 264: 14256–14261, 1989.
13. Pastan, I., Lovelace, E. T., Gallo, M. G., Rutherford, A. V., Magnani, J. L., and Willingham, M. C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res., 51: 3781–3787, 1991.
14. Pai, L. H., and Pastan, I. Immunotoxin therapy for cancer. JAMA (J. Am. Med. Assoc.), 269: 78–81, 1993.
15. Pai, L. H., Wittes, R. E., Setser, A., Goldspiel, B., FitzGerald, D., Willingham, M. C., and Pastan, I. Phase I study of the immunotoxin LMB-1, an anti-cancer murine MAb B3, coupled to a recombinant form of Pseudomonas exotoxin, PE38. Proc. Am. Assoc. Cancer Res., 35: 507, 1994.
16. Siegel, J. P., and Puri, R. K. Interleukin-2 toxicity. J. Chem. Oncol., 9: 694–704, 1991.
17. Damle, N. K., and Doyle, L. V. IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers: implications for vascular leak syndrome. J. Immunol., 142: 2660–2669, 1989.
18. Soler-Rodriguez, A. M., Ghetie, M. A., Oppenheimer-Marks, N., Uhr, J. W., and Vitetta, E. S. Ricin A chain and ricin A chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res., 206: 227–234, 1993.
19. Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M., and Pastan, I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA, 88: 8616–8620, 1991.
20. Kreitman, R. J., Bailon, P., Chaudhary, V. K., FitzGerald, D. J., and Pastan, I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood, 83: 426–434, 1994.
21. Pai, L. H., Batra, J. K., FitzGerald, D. J., Willingham, M. C., and Pastan, I. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 88: 3358–3362, 1991.
22. Reiter, Y., Brinkmann, U., Jung, S-H., Lee, B., Kasprzyk, P., King, C. R., and Pastan, I. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem., 269: 18327–18331, 1994.
23. Kounnas, M. Z., Morris, R. E., Thompson, M. R., FitzGerald, D. J., Strickland, D. K., and Saelinger, C. B. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. Biol. Chem., 267; 12420–12423, 1993.
24. Reiter, Y., Brinkmann, U., Webber, K. O., Jung, S-H., Lee, B., and Pastan, I. Engineering interchain disulfide bonds into conserved framework region of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng., 7: 697–704, 1994.
25. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867–5871, 1992.